Apoptosis and cell growth arrest in A375 human melanoma cells by diorganotin(IV) and triorganotin(IV) complexes of [meso-Tetra(4-sulfonatophenyl) porphine] manganese(III)chloride

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 693-700

  Costa, Maria Assunta ^a   Zito, Francesca ^a   Emma, Maria Rita ^a   Pellerito, Lorenzo ^b   Fiore, Tiziana ^b   Pellerito, Claudia ^b   Barbieri, Giovanna ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

catenin; c myc; Cell viability; Hoechst; Snail

Indexed keywords

BETA CATENIN; MYC PROTEIN; ORGANOTIN COMPOUND; TETRAKIS(4 SULFOPHENYL)PORPHINE; TRANSCRIPTION FACTOR SNAIL;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL FRACTIONATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFICACY; FLUORESCENCE; HUMAN; HUMAN CELL; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SPINDLE CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLORIDES; DNA FRAGMENTATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MANGANESE COMPOUNDS; MELANOMA; METALLOPORPHYRINS; ORGANOTIN COMPOUNDS; PORPHYRINS; SKIN NEOPLASMS;

EID: 79952035674     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.889     Document Type: Article

References (43)

1. Vicente MG: Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr Med Chem Anticancer Agents 1: 175-194, 2001.
2. Tita SP and Perussi JR: The effect of porphyrins on normal and transformed mouse cell lines in the presence of visible light. Braz J Med Biol Res 34: 1331-1336, 2001. (Pubitemid 33014502)
3. Pushpan SK, Venkatraman S, Anand VG, Sankar J, Parmeswaran D, Ganesan S and Chandrashekar TK: Porphyrins in photodynamic therapy - a search for ideal photosensitizers. Curr Med Chem Anticancer Agents 2: 187-207, 2002. (Pubitemid 34657137)
4. Chwikowska A, Saczko J, Modrzycka T, Marcinkowska A, Malarska A, Bielewicz J, Palatas D and Banas T: Uptake of photofrin II, a photosensitizer used in photodynamic therapy, by tumour cells in vitro. Acta Biochimica Polonica 50: 509-513, 2003. (Pubitemid 37034703)
5. Babilas P, Karrer S, Sidoroff A, Landthaler M and Szeimies RM: Photodynamic therapy in dermatology - an update. Photodermatol Photoimmunol Photomed 21: 142-149, 2005. (Pubitemid 40778615)
6. O'Connor AE, Gallagher WM and Byrne AT: Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 85: 1053-1074, 2009.
7. Nadeau V, O'Dwyer M, Hamdan K, Tait I and Padgett M: In vivo measurement of 5-aminolaevulinic acid-induced protoporphyrin IX photobleaching: a comparison of red and blue light of various intensities. Photodermatol Photoimmunol Photomed 20: 170-174, 2004.
8. Pogue BW, Sheng C, Benevides J, Forcione D, Puricelli B, Nishioka N and Hasan T: Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. J Biomed Opt 13: 034009, 2008.
9. Zeitouni NC, Oseroff AR and Shieh S: Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol 39: 1133-1136, 2003.
10. Mat LW, Nielsen KP, Iani V and Moan J: A new method for photodynamic therapy of melanotic melanoma-effects of depigmentation with violet light photodynamic therapy. J Environ Pathol Toxicol Oncol 26: 165-172, 2007.
11. 2-(.). Free Radic Biol Med 11: 1-8, 1991.
12. Zhou Z, Li CY, Li K, Wang T, Zhang B and Gao TW: Decreased methionine sulphoxide reductase A expression renders melanocytes more sensitive to oxidative stress: a possible cause for melanocyte loss in vitiligo. Br J Dermatol 161: 504-509, 2009.
13. Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature 445: 851-857, 2007.
14. Pellerito A, Fiore T, Giuliani AM, Maggio F, Pellerito L and Mansueto C: Organometallic complexes with biological molecules: IX. Diorgano-and Triorgano-tin(IV)[meso-tetra(4-sulfonatophenyl)porphinate] derivates: solid-state and solutio-phase structural aspects and in vivo effects. Appl Organomet Chem 11: 707-719, 1997. (Pubitemid 127523248)
15. Mansueto C, Puccia E, Maggio F, Di Stefano R, Fiore T, Pellerito C, Triolo F and Pellerito L: Organometallic complexes with biological molecules. XIV. Biological activity of Dialkyl and Trialkyltin(IV) [meso-tetra(4-carboxy- phenyl)porphinate] derivates. Appl Organomet Chem 14: 229-235, 2000.
16. Han G and Yang P: Synthesis and characterization of water-insoluble and water-soluble dibutyltin(IV) porphinate complexes based on the tris(pyridinyl)porphyrin moiety, their anti-tumor activity in vitro and interaction with DNA. J Inorg Biochem 91: 230-236, 2002. (Pubitemid 34727773)
17. Wongsinkongman P, Brossi A, Wang HK, Bastow KF and Lee KH: Antitumor agents. Part 209: pheophorbide - a derivatives as photo-independent cytotoxic agents. Bioorg Med Chem 10: 583-591, 2002.
18. Costa MA, Pellerito L, Izzo V, Fiore T, Pellerito C, Melis M, Musmeci MT and Barbieri G: Diorganotin(IV) and triorganotin(IV) complexes of meso-tetra(4-sulfonatophenil)porphine induce apoptosis in A375 human melanoma cells. Cancer Lett 238: 284-294, 2006.
19. Costa MA, Gulino L, Pellerito L, Fiore T, Pellerito C and Barbieri G: Effects of two organotin(IV)(sulfonatophenyl) porphinates on MAPKs and on the growth of A375 human melanoma cells. Oncol Rep 21: 593-599, 2009.
20. Pellerito C, Scopelliti M, Fiore T, Nagy L, Barone G, Abbate M, Stocco GC and Pellerito L: Structural investigations on diorgano- and triorganotin(IV) derivatives of [meso-tetra(4-sulfonatophenyl) porphine] metal chlorides. J Organomet Chem 691: 1573-1583, 2006.
21. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
22. Izzo V, Asaro MR, Forte GI and Barbieri R: Use of voltage gradient gel electrophoresis in apoptotic DNA analysis. J Chromatogr A 890: 371-374, 2000. (Pubitemid 30621578)
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
24. Zhang Y, Wang H and Yang RH: Colorimetric and fluorescent sensing of SCN-based on meso-tetraphenylporphyrin cobalt(II) system. Sensors 7: 410-419, 2007.
25. Gonçalves PJ, De Boni L, Borissevitch IE and Zìlio SC: Excited state dynamics of meso-tetra(sulphonatophenyl) metalloporphyrins. J Phys Chem A 112: 6522-6526, 2008.
26. Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T and Nakagawa H: Constitutive activation of Wnt/β-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 288: 8-15, 2001. (Pubitemid 32999718)
27. Biroccio A, Amodei S, Antonelli A, Benassi B and Zupi G: Inhibition of c-myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem 278: 35693-35701, 2003. (Pubitemid 37102344)
28. Palmer MB, Majumder P, Green MR, Wade PA and Boss JM: A 3′ enhancer controls snail expression in melanoma cells. Cancer Res 67: 6113-6120, 2007. (Pubitemid 47037491)
29. Serrone L, Zeuli M, Sega FM and Cognetti F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19: 21-34, 2000. (Pubitemid 30305516)
30. Soengas MS and Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151, 2003. (Pubitemid 36713766)
31. Alama A, Tasso B, Novelli F and Sparatore F: Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov Today 14: 500-508, 2009.
32. Polo L, Valduga G, Jori G and Reddi E: Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol 34: 10-23, 2002. (Pubitemid 33152910)
33. Peifer M and Polakis P: Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science 287: 1606-1609, 2000. (Pubitemid 30127755)
34. Boxer LM and Dang CV: Translocations involving c-myc and c-myc function. Oncogene 20: 5595-5610, 2001. (Pubitemid 32928100)
35. Medici D, Hay ED and Olsen BR: Snail and Slug promote epithelial-mesenchymal transition through β-catenin-T-cell factor-4-dependent expression of transforming growth factor-β3. Mol Biol Cell 19: 4875-4887, 2008.
36. Tucci MG, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, Giacchetti A, Ricotti G and Biagini G: Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 157: 1212-1216, 2007. (Pubitemid 350115706)
37. Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 15: 5615-5620, 2009.
38. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fässler R and Bosserhoff AK: Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206: 221-232, 2009.
39. Conacci-Sorrell M, Zhurinsky J and Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109: 987-991, 2002. (Pubitemid 34408571)
40. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746, 2003.
41. Cho KB, Cho MK, Lee WY and Kang KW: Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett 293: 230-239, 2010.
42. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP and Larue L: IGF-II induces rapid ß-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20: 4942-4950, 2001. (Pubitemid 32769784)
43. Raz A: Actin organization, cell motility and metastasis. Adv Exper Med Biol 233: 227-233, 1988.